iRhythm Technologies, Inc.

Equities

IRTC

US4500561067

Advanced Medical Equipment & Technology

Market Closed - Nasdaq 04:30:01 2024-03-28 pm EDT 5-day change 1st Jan Change
116 USD +0.21% Intraday chart for iRhythm Technologies, Inc. +5.95% +8.37%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
IRhythm Technologies Closes $661 Million Notes Offering MT
Irhythm Technologies Insider Sold Shares Worth $360,983, According to a Recent SEC Filing MT
IRhythm Technologies Prices $575 Million Convertible Notes Offering MT
IRhythm Shares Fall After Firm Plans $450 Million Convertible Notes Offering MT
IRhythm Technologies Plans to Offer $450 in Convertible Notes Due 2029 MT
Needham Adjusts iRhythm Technologies' Price Target to $137 From $136, Keeps Buy Rating MT
IRhythm Technologies Q4 Adjusted Loss Widens, Revenue Rises; 2024 Sales Outlook Set -- Shares Slump After Hours MT
Transcript : IRhythm Technologies, Inc., Q4 2023 Earnings Call, Feb 22, 2024
IRhythm Technologies, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 CI
IRhythm Technologies, Inc. Provides Earnings Guidance for the Year 2024 CI
IRhythm Technologies, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Transcript : IRhythm Technologies, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-08-2024 04:30 PM
IRhythm Technologies Closes $150 Million Debt Facility; 2024 Revenue Forecast Issued MT
Needham Raises iRhythm Technologies' Price Target to $136 From $108, Keeps Buy Rating MT
Irhythm Technologies, Inc. Entered into A Credit, Security and Guaranty Agreement with Braidwell Transaction Holdings LLC CI
IRhythm Technologies, Inc. Revises Revenue Guidance for the Year 2024 CI
IRhythm Technologies Says Study Shows Zio Has 'Higher Diagnostic Yield' Compared With Other Cardiac Monitors MT
IRhythm , Inc. Announces Results from the Cardiac Ambulatory Monitor EvaLuation of Outcomes and Time to Events CI
Irhythm Technologies Insider Sold Shares Worth $745,692, According to a Recent SEC Filing MT
IRhythm Technologies Says it Obtained EU CE Mark for Zio Monitor, Zeus System MT
Truist Securities Adjusts iRhythm Technologies Price Target to $115 From $100, Maintains Buy Rating MT
North American Morning Briefing : Traders Eye -2- DJ
Citigroup Upgrades iRhythm Technologies to Buy From Neutral, Raises Price Target to $110 From $85 MT
Transcript : IRhythm Technologies, Inc., Q3 2023 Earnings Call, Nov 02, 2023
Earnings Flash (IRTC) IRHYTHM Posts Q3 Revenue $124.6M, vs. Street Est of $122.6M MT
Chart iRhythm Technologies, Inc.
More charts
iRhythm Technologies, Inc. is a digital health care company, which creates solutions that detect, predict, and prevent disease. The Company designs, develops, and commercializes device-based technology to provide ambulatory cardiac monitoring services. It offers three Zio System options: the Zio Monitor System, the Zio XT System, and the Zio AT System. It offers its Zio ambulatory cardiac monitoring services, including long-term continuous monitoring, short-term continuous monitoring, and mobile cardiac telemetry monitoring services (Zio Services), using its Zio Systems. The Zio Monitor System is a prescription-only, remote ECG monitoring system that consists of a patch ECG monitor (the Zio Monitor patch) that records the electric signal from the heart continuously for up to 14 days and the Zio ECG Utilization Software (ZEUS) System, which supports the capture and analysis of ECG data recorded by the Zio Monitor patch at the end of the wear period.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
116 USD
Average target price
138.5 USD
Spread / Average Target
+19.40%
Consensus
  1. Stock
  2. Equities
  3. Stock iRhythm Technologies, Inc. - Nasdaq
  4. News iRhythm Technologies, Inc.
  5. BTIG Upgrades IRhythm Technologies to Buy From Neutral; Price Target is $170